Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) : A representative and useful real-life data source for further biomedical research.

Geissler K, Jäger E, Barna A, Gurbisz M, Marschon R, Graf T, Graf E, Borjan B, Jilch R, Geissler C, Hoermann G, Esterbauer H, Schwarzinger I, Nösslinger T, Pfeilstöcker M, Tüchler H, Reisner R, Sliwa T, Keil F, Bettelheim P, Machherndl-Spandl S, Doleschal B, Zach O, Weltermann A, Heibl S, Thaler J, Zebisch A, Sill H, Stauder R, Webersinke G, Petzer A, Kusec R, Ulsperger E, Schneeweiss B, Berger J, Öhler L, Germing U, Sperr WR, Knöbl P, Jäger U, Valent P.

Wien Klin Wochenschr. 2019 Sep;131(17-18):410-418. doi: 10.1007/s00508-019-1526-1. Epub 2019 Jul 18.

2.

CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation.

Raimbault A, Machherndl-Spandl S, Itzykson R, Clauser S, Chapuis N, Mathis S, Lauf J, Alary AS, Burroni B, Kosmider O, Fontenay M, Béné MC, Durrieu F, Bettelheim P, Bardet V.

Br J Haematol. 2019 Feb;184(4):625-633. doi: 10.1111/bjh.15584. Epub 2018 Sep 10.

PMID:
30198568
3.

Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts.

Valent P, Büsche G, Theurl I, Uras IZ, Germing U, Stauder R, Sotlar K, Füreder W, Bettelheim P, Pfeilstöcker M, Oberbauer R, Sperr WR, Geissler K, Schwaller J, Moriggl R, Béné MC, Jäger U, Horny HP, Hermine O.

Haematologica. 2018 Oct;103(10):1593-1603. doi: 10.3324/haematol.2018.192518. Epub 2018 Aug 3. Review.

4.

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.

Schneeweiss M, Peter B, Bibi S, Eisenwort G, Smiljkovic D, Blatt K, Jawhar M, Berger D, Stefanzl G, Herndlhofer S, Greiner G, Hoermann G, Hadzijusufovic E, Gleixner KV, Bettelheim P, Geissler K, Sperr WR, Reiter A, Arock M, Valent P.

Haematologica. 2018 May;103(5):799-809. doi: 10.3324/haematol.2017.179895. Epub 2018 Feb 8.

5.

Diagnosis, management and response criteria of iron overload in myelodysplastic syndromes (MDS): updated recommendations of the Austrian MDS platform.

Valent P, Stauder R, Theurl I, Geissler K, Sliwa T, Sperr WR, Bettelheim P, Sill H, Pfeilstöcker M.

Expert Rev Hematol. 2018 Feb;11(2):109-116. doi: 10.1080/17474086.2018.1420473. Epub 2018 Jan 2. Review.

PMID:
29292655
6.

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions.

Valent P, Orazi A, Steensma DP, Ebert BL, Haase D, Malcovati L, van de Loosdrecht AA, Haferlach T, Westers TM, Wells DA, Giagounidis A, Loken M, Orfao A, Lübbert M, Ganser A, Hofmann WK, Ogata K, Schanz J, Béné MC, Hoermann G, Sperr WR, Sotlar K, Bettelheim P, Stauder R, Pfeilstöcker M, Horny HP, Germing U, Greenberg P, Bennett JM.

Oncotarget. 2017 Jul 5;8(43):73483-73500. doi: 10.18632/oncotarget.19008. eCollection 2017 Sep 26.

7.

The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells.

Stefanzl G, Berger D, Cerny-Reiterer S, Blatt K, Eisenwort G, Sperr WR, Hoermann G, Lind K, Hauswirth AW, Bettelheim P, Sill H, Melo JV, Jäger U, Valent P.

Oncotarget. 2017 Jun 28;8(40):67709-67722. doi: 10.18632/oncotarget.18810. eCollection 2017 Sep 15.

8.

Proposed diagnostic criteria and classification of basophilic leukemias and related disorders.

Valent P, Sotlar K, Blatt K, Hartmann K, Reiter A, Sadovnik I, Sperr WR, Bettelheim P, Akin C, Bauer K, George TI, Hadzijusufovic E, Wolf D, Gotlib J, Mahon FX, Metcalfe DD, Horny HP, Arock M.

Leukemia. 2017 Apr;31(4):788-797. doi: 10.1038/leu.2017.15. Epub 2017 Jan 16. Review.

PMID:
28090091
9.

Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group.

Westers TM, Cremers EM, Oelschlaegel U, Johansson U, Bettelheim P, Matarraz S, Orfao A, Moshaver B, Brodersen LE, Loken MR, Wells DA, Subirá D, Cullen M, Te Marvelde JG, van der Velden VH, Preijers FW, Chu SC, Feuillard J, Guérin E, Psarra K, Porwit A, Saft L, Ireland R, Milne T, Béné MC, Witte BI, Della Porta MG, Kern W, van de Loosdrecht AA; IMDSFlow Working Group.

Haematologica. 2017 Feb;102(2):308-319. doi: 10.3324/haematol.2016.147835. Epub 2016 Oct 6.

10.

10th anniversary of the Austrian MDS Platform: aims and ongoing projects.

Burgstaller S, Bettelheim P, Krieger O, Machherndl-Spandl S, Nösslinger T, Pleyer L, Sill H, Sperr WR, Stauder R, Valent P, Pfeilstöcker M.

Wien Klin Wochenschr. 2015 Jan;127(1-2):12-5. doi: 10.1007/s00508-014-0627-0. Epub 2014 Nov 25.

PMID:
25421367
11.

Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage.

Valent P, Berger J, Cerny-Reiterer S, Peter B, Eisenwort G, Hoermann G, Müllauer L, Mannhalter C, Steurer M, Bettelheim P, Horny HP, Arock M.

Ann Hematol. 2015 Feb;94(2):223-31. doi: 10.1007/s00277-014-2207-9. Epub 2014 Sep 11.

12.

Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS.

Porwit A, van de Loosdrecht AA, Bettelheim P, Brodersen LE, Burbury K, Cremers E, Della Porta MG, Ireland R, Johansson U, Matarraz S, Ogata K, Orfao A, Preijers F, Psarra K, Subirá D, Valent P, van der Velden VH, Wells D, Westers TM, Kern W, Béné MC.

Leukemia. 2014 Sep;28(9):1793-8. doi: 10.1038/leu.2014.191. Epub 2014 Jun 12.

PMID:
24919805
13.

Qualifying high-throughput immune repertoire sequencing.

Niklas N, Pröll J, Weinberger J, Zopf A, Wiesinger K, Krismer K, Bettelheim P, Gabriel C.

Cell Immunol. 2014 Mar-Apr;288(1-2):31-8. doi: 10.1016/j.cellimm.2014.02.001. Epub 2014 Feb 23.

PMID:
24607567
14.

Molecular pathways of early CD105-positive erythroid cells as compared with CD34-positive common precursor cells by flow cytometric cell-sorting and gene expression profiling.

Machherndl-Spandl S, Suessner S, Danzer M, Proell J, Gabriel C, Lauf J, Sylie R, Klein HU, Béné MC, Weltermann A, Bettelheim P.

Blood Cancer J. 2013 Jan 11;3:e100. doi: 10.1038/bcj.2012.45.

15.

Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group.

van de Loosdrecht AA, Ireland R, Kern W, Della Porta MG, Alhan C, Balleisen JS, Bettelheim P, Bowen DT, Burbury K, Eidenschink L, Cazzola M, Chu SS, Cullen M, Cutler JA, Dräger AM, Feuillard J, Fenaux P, Font P, Germing U, Haase D, Hellström-Lindberg E, Johansson U, Kordasti S, Loken MR, Malcovati L, te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Nikolova V, Ogata K, Oelschlaegel U, Orfao A, Ossenkoppele GJ, Porwit A, Platzbecker U, Preijers F, Psarra K, Richards SJ, Subirá D, Seymour JF, Tindell V, Vallespi T, Valent P, van der Velden VH, Wells DA, de Witte TM, Zettl F, Béné MC, Westers TM.

Leuk Lymphoma. 2013 Mar;54(3):472-5. doi: 10.3109/10428194.2012.718341. Epub 2012 Sep 14. Review.

PMID:
22916713
16.

Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group.

Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P, Burbury K, Cullen M, Cutler JA, Della Porta MG, Dräger AM, Feuillard J, Font P, Germing U, Haase D, Johansson U, Kordasti S, Loken MR, Malcovati L, te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Ogata K, Orfao A, Porwit A, Psarra K, Richards SJ, Subirá D, Tindell V, Vallespi T, Valent P, van der Velden VH, de Witte TM, Wells DA, Zettl F, Béné MC, van de Loosdrecht AA.

Leukemia. 2012 Jul;26(7):1730-41. doi: 10.1038/leu.2012.30. Epub 2012 Feb 6.

PMID:
22307178
17.

Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10.

Béné MC, Nebe T, Bettelheim P, Buldini B, Bumbea H, Kern W, Lacombe F, Lemez P, Marinov I, Matutes E, Maynadié M, Oelschlagel U, Orfao A, Schabath R, Solenthaler M, Tschurtschenthaler G, Vladareanu AM, Zini G, Faure GC, Porwit A.

Leukemia. 2011 Apr;25(4):567-74. doi: 10.1038/leu.2010.312. Epub 2011 Jan 21. Review.

PMID:
21252983
18.

A European consensus report on blood cell identification: terminology utilized and morphological diagnosis concordance among 28 experts from 17 countries within the European LeukemiaNet network WP10, on behalf of the ELN Morphology Faculty.

Zini G, Bain B, Bettelheim P, Cortez J, d'Onofrio G, Faber E, Haferlach T, Kacirkova P, Lewandowski K, Matutes E, Maynadié M, Meletis J, Petersen BL, Porwit A, Terpos E, Tichelli A, Vallespí T, Woessner S, Bennett J, Bene MC.

Br J Haematol. 2010 Nov;151(4):359-64. doi: 10.1111/j.1365-2141.2010.08366.x.

PMID:
20812999
19.

Meeting report: Vienna 2008 Workshop of the German-Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes.

Valent P, Hofmann WK, Büsche G, Sotlar K, Horny HP, Haase D, Haferlach T, Kern W, Bettelheim P, Baumgartner C, Sperr WR, Nösslinger T, Wimazal F, Giagounidis AA, Lübbert M, Krieger O, Kolb HJ, Stauder R, Pfeilstöcker M, Gattermann N, Fonatsch C, Aul C, Germing U.

Ann Hematol. 2009 Jul;88(7):607-11. doi: 10.1007/s00277-008-0673-7. Epub 2009 Jan 16.

PMID:
19148644
20.

Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform.

Valent P, Krieger O, Stauder R, Wimazal F, Nösslinger T, Sperr WR, Sill H, Bettelheim P, Pfeilstöcker M.

Eur J Clin Invest. 2008 Mar;38(3):143-9. doi: 10.1111/j.1365-2362.2007.01915.x. Epub 2008 Jan 24.

21.

Impact of the factor II: G20210A variant on the risk of venous thromboembolism in relatives from families with the factor V: R506Q mutation.

Rintelen C, Pabinger I, Bettelheim P, Lechner K, Kyrle PA, Knöbl P, Schneider B, Mannhalter C.

Eur J Haematol. 2001 Sep;67(3):165-9.

PMID:
11737249
22.

Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison.

Kern W, Aul C, Maschmeyer G, Schönrock-Nabulsi R, Ludwig WD, Bartholomäus A, Bettelheim P, Wörmann B, Büchner T, Hiddemann W.

Leukemia. 1998 Jul;12(7):1049-55.

23.

Chemotherapy in patients with acquired immunodeficiency virus syndrome associated with non-Hodgkin's lymphoma.

Fridrik MA, Geit M, Wahl G, Ehrengruber A, Simma R, Höpfel I, Bettelheim P, Leisch F.

Wien Klin Wochenschr. 1998 Jan 16;110(1):15-9. Review.

PMID:
9499473
24.

First-line treatment of Waldenström's disease with cladribine. Arbeitsgemeinschaft Medikamentöse Tumortherapie.

Fridrik MA, Jäger G, Baldinger C, Krieger O, Chott A, Bettelheim P.

Ann Hematol. 1997 Jan;74(1):7-10.

PMID:
9031608
25.

Autoimmune reactions in patients with silicone breast implants.

Zazgornik J, Piza H, Kaiser W, Bettelheim P, Steiner G, Smolen J, Biesenbach G, Maschek W.

Wien Klin Wochenschr. 1996 Dec 27;108(24):781-7.

PMID:
9017890
26.

Factors influencing the timing of peripheral blood stem cell collection (PBSC).

Kasparu H, Krieger O, Girschikofsky M, Kolb A, Bettelheim P, Lutz D.

Transfus Sci. 1996 Dec;17(4):595-600.

PMID:
10168558
27.

Mast cell-lineage versus basophil lineage involvement in myeloproliferative and myelodysplastic syndromes: diagnostic role of cell-immunophenotyping.

Agis H, Beil WJ, Bankl HC, Füreder W, Sperr WR, Ghannadan M, Baghestanian M, Sillaber C, Bettelheim P, Lechner K, Valent P.

Leuk Lymphoma. 1996 Jul;22(3-4):187-204. Review.

PMID:
8819068
28.

Immunophenotypic analysis of HL-60 cells during basophilic differentiation.

Wong DA, Valent P, Bettelheim P, Switzer J, Denburg JA.

Int Arch Allergy Immunol. 1996 Jul;110(3):252-60.

PMID:
8688672
29.

Metabolic responses after laparoscopic or open hernia repair.

Schrenk P, Bettelheim P, Woisetschläger R, Rieger R, Wayand WU.

Surg Endosc. 1996 Jun;10(6):628-32.

PMID:
8662400
30.

Potentiation of granulocyte colony-stimulating factor-induced mobilization of circulating progenitor cells by seven-day pretreatment with interleukin-3.

Geissler K, Peschel C, Niederwieser D, Strobl H, Goldschmitt J, Ohler L, Bettelheim P, Kahls P, Huber C, Lechner K, Höcker P, Kolbe K.

Blood. 1996 Apr 1;87(7):2732-9.

PMID:
8639889
31.

Effect of interleukin-3 pretreatment on granulocyte/macrophage colony-stimulating factor induced mobilization of circulating haemopoietic progenitor cells.

Geissler K, Peschel C, Niederwieser D, Goldschmitt J, Hladik F, Fritz A, Ohler L, Bettelheim P, Huber C, Lechner K, et al.

Br J Haematol. 1995 Oct;91(2):299-305.

PMID:
8547065
32.

[Autologous stem cell harvesting after high dosage chemo- and/or growth factor therapy].

Kasparu H, Krieger O, Bettelheim P, Kolb A, Lutz D.

Wien Med Wochenschr. 1995;145(2-3):58-60. German.

PMID:
7539197
33.

Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass.

Blauhut B, Harringer W, Bettelheim P, Doran JE, Späth P, Lundsgaard-Hansen P.

J Thorac Cardiovasc Surg. 1994 Dec;108(6):1083-91.

PMID:
7527112
34.

High efficacy of the German multicenter ALL (GMALL) protocol for treatment of adult acute lymphoblastic leukemia (ALL)--a single-institution study.

Scherrer R, Bettelheim P, Geissler K, Jäger U, Knöbl P, Kyrle PA, Laczika K, Mitterbauer G, Neumann E, Schneider B, et al.

Ann Hematol. 1994 Oct;69(4):181-8.

PMID:
7948304
35.

Tumor necrosis factor alpha and interleukin-1 beta mRNA expression in HMC-1 cells: differential regulation of gene product expression by recombinant interleukin-4.

Sillaber C, Bevec D, Butterfield JH, Heppner C, Valenta R, Scheiner O, Kraft D, Lechner K, Bettelheim P, Valent P.

Exp Hematol. 1993 Aug;21(9):1271-5.

PMID:
8330651
37.

Granulocyte colony-stimulating factor (G-CSF) as an adjunct to induction chemotherapy of adult acute lymphoblastic leukemia (ALL).

Scherrer R, Geissler K, Kyrle PA, Gisslinger H, Jäger U, Bettelheim P, Laczika K, Locker G, Scholten C, Sillaber C, et al.

Ann Hematol. 1993 Jun;66(6):283-9.

PMID:
7686404
38.

High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison.

Hiddemann W, Aul C, Maschmeyer G, Schönrock-Nabulsi R, Ludwig WD, Bartholomäus A, Bettelheim P, Becker K, Balleisen L, Lathan B, et al.

Leuk Lymphoma. 1993;10 Suppl:133-7.

PMID:
8481662
39.

Combination treatment of acute myeloblastic leukemia with rhGM-CSF and standard induction chemotherapy.

Valent P, Sillaber C, Geissler K, Andreeff M, Tafuri A, Vieder L, Schulz G, Lechner K, Bettelheim P.

Cancer Invest. 1993;11(2):229-34. No abstract available.

PMID:
8462024
40.

Recurrent, isolated factor X deficiency in myeloma: repeated normalization of factor X levels after cytostatic chemotherapy followed by late treatment failure associated with the development of systemic amyloidosis.

Schwarzinger I, Stain-Kos M, Bettelheim P, Pabinger I, Kyrle P, Kalhs P, Kapiotis S, Jäger U, Lechner K.

Thromb Haemost. 1992 Dec 7;68(6):648-51.

PMID:
1287879
41.

Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture.

Valent P, Spanblöchl E, Sperr WR, Sillaber C, Zsebo KM, Agis H, Strobl H, Geissler K, Bettelheim P, Lechner K.

Blood. 1992 Nov 1;80(9):2237-45.

PMID:
1384799
42.

Type beta transforming growth factors promote interleukin-3 (IL-3)-dependent differentiation of human basophils but inhibit IL-3-dependent differentiation of human eosinophils.

Sillaber C, Geissler K, Scherrer R, Kaltenbrunner R, Bettelheim P, Lechner K, Valent P.

Blood. 1992 Aug 1;80(3):634-41.

PMID:
1379084
43.

Characterization of prostaglandin (PG)-binding sites expressed on human basophils. Evidence for a prostaglandin E1, I2, and a D2 receptor.

Virgolini I, Li S, Sillaber C, Majdic O, Sinzinger H, Lechner K, Bettelheim P, Valent P.

J Biol Chem. 1992 Jun 25;267(18):12700-8.

44.

Detection of circulating endogenous interleukin-3 in extensive chronic graft-versus-host disease.

Valent P, Sillaber KC, Scherrer R, Geissler K, Kier P, Kalhs P, Kundi M, Papoian R, Bettelheim P, Hinterberger W, et al.

Bone Marrow Transplant. 1992 May;9(5):331-6.

PMID:
1617317
45.

In vivo synergism of recombinant human interleukin-3 and recombinant human interleukin-6 on thrombopoiesis in primates.

Geissler K, Valent P, Bettelheim P, Sillaber C, Wagner B, Kyrle P, Hinterberger W, Lechner K, Liehl E, Mayer P.

Blood. 1992 Mar 1;79(5):1155-60.

PMID:
1536942
46.

Simultaneous occurrence of t(14;18) and t(8;22) common acute lymphoblastic leukemia.

Marosi C, Bettelheim P, Chott A, Köller U, Kreiner G, Steger G, Jäger U, Pirc-Danoewinata H, Lechner K.

Ann Hematol. 1992 Feb;64(2):101-4.

PMID:
1554791
47.

Cell surface structures on human basophils and mast cells: biochemical and functional characterization.

Valent P, Bettelheim P.

Adv Immunol. 1992;52:333-423. Review. No abstract available.

PMID:
1332448
49.

IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells.

Sillaber C, Strobl H, Bevec D, Ashman LK, Butterfield JH, Lechner K, Maurer D, Bettelheim P, Valent P.

J Immunol. 1991 Dec 15;147(12):4224-8.

PMID:
1721642
50.

Identification of profilin as a novel pollen allergen; IgE autoreactivity in sensitized individuals.

Valenta R, Duchêne M, Pettenburger K, Sillaber C, Valent P, Bettelheim P, Breitenbach M, Rumpold H, Kraft D, Scheiner O.

Science. 1991 Aug 2;253(5019):557-60.

PMID:
1857985

Supplemental Content

Loading ...
Support Center